Stock Events

Stock Events

Kyntra Bio 

$7.01
0
-$0.09-1.27% Thursday 20:00

Statistics

Day High
7.4
Day Low
7.01
52W High
12.6
52W Low
4.85
Volume
6,178
Avg. Volume
33,798
Mkt Cap
28.36M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-4.01
13.87
31.74
49.61
Expected EPS
-3.355
Actual EPS
N/A

Financials

-23.41%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
406.57MRevenue
-95.16MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KYNB. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Akebia Therapeutics
AKBA
Mkt Cap585.97M
Akebia Therapeutics competes in the anemia market, particularly in chronic kidney disease (CKD), similar to FibroGen's roxadustat.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline competes with FibroGen in developing treatments for anemia associated with CKD, through their product daprodustat.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca collaborates with FibroGen on roxadustat but also competes in broader therapeutic areas relevant to FibroGen's interests.
AMGEN
AMGN
Mkt Cap160.66B
Amgen, with its portfolio of erythropoiesis-stimulating agents (ESAs) for anemia treatment, competes in the same therapeutic area as FibroGen.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in treating cystic fibrosis and other serious diseases, competing with FibroGen's fibrosis research efforts.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on rare diseases, including some areas that overlap with FibroGen's interest in rare fibrotic conditions.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad portfolio that includes treatments for fibrosis and cancer, directly competing with several of FibroGen's development programs.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a strong presence in the treatment of fibrotic diseases, especially with its drug for idiopathic pulmonary fibrosis, competing with FibroGen's fibrosis pipeline.

About

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Show more...
CEO
Mr. Thane Wettig
Employees
225
Country
US
ISIN
US31572Q8814

Listings

F
DE
1FG0.F
LSE
GB
0IL8.LSE
MX
MX
KYNB.MX
XNAS
US
KYNB

0 Comments

Share your thoughts

FAQ

What is Kyntra Bio stock price today?▼
The current price of KYNB is $7.01 USD — it has decreased by -1.27% in the past 24 hours. Watch Kyntra Bio stock price performance more closely on the chart.
What is Kyntra Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kyntra Bio stocks are traded under the ticker KYNB.
What is Kyntra Bio market cap?▼
Today Kyntra Bio has the market capitalization of 28.36M
When is the next Kyntra Bio earnings date?▼
Kyntra Bio is going to release the next earnings report on May 11, 2026.
What were Kyntra Bio earnings last quarter?▼
KYNB earnings for the last quarter are -3.51 USD per share, whereas the estimation was -3.89 USD resulting in a +9.65% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Kyntra Bio revenue for the last year?▼
Kyntra Bio revenue for the last year amounts to 406.57M USD.
What is Kyntra Bio net income for the last year?▼
KYNB net income for the last year is -95.16M USD.
How many employees does Kyntra Bio have?▼
As of April 04, 2026, the company has 225 employees.
In which sector is Kyntra Bio located?▼
Kyntra Bio operates in the Health Care sector.
When did Kyntra Bio complete a stock split?▼
The last stock split for Kyntra Bio was on June 17, 2025 with a ratio of 1:25.
Where is Kyntra Bio headquartered?▼
Kyntra Bio is headquartered in San Francisco, US.